Virbac Stock Falls Below Its Three Moving Averages Mid-Session
The veterinary laboratory in Carros declines midday in a downward trending Paris market. The stock erases part of its rebound from the end of last week and falls below key technical levels. The overall context remains weighed down by the rise in Brent and the strength of the dollar.
Virbac Stock Drops 1.71% in Session Amid Broader Market Decline
Virbac stock loses 1.71% to €344.00 during the session, while the SBF 120 is down 0.45% and the CAC 40 drops 0.48%. The stock ranks beyond the hundredth position in the broad index, not featuring among the extreme movements of the day. The decline erases the rebound that began last Friday, documented at the end of last week. Over a month, the loss is 7%, while the annual gain remains at 5.7%. The market context continues to be heavy. Brent has risen above $95 following new strikes in Lebanon, and the dollar is at a two-month high after a strong U.S. employment report. These two factors do not directly affect the veterinary laboratory but add to the general gloom over European stocks.
Crossing Below Three Moving Averages, Approaching the €339 Support
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The price falls below its three moving averages: the MM20 at €353.00 (a gap of -2.55%), the MM50 at €359.74 (-4.38%), and the MM200 at €348.83 (-1.38%). This configuration indicates a loss of momentum in the short and medium term. The RSI at 45 remains in the neutral zone, with no sign of seller exhaustion. The identified support at €339.00 is now about 1.5% below the current price, and will be the next level to watch if the slide continues. The upper resistance remains at €378.50, a level approached in May after TP Icap raised its target to €412 in mid-May. The underlying trend remains one of consolidation, with the stock now operating in the lower half of its recent channel.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.